Inhibikase Therapeutics Stock Cash And Equivalents
| IKT Stock | USD 2.31 0.30 14.93% |
Inhibikase Therapeutics fundamentals help investors to digest information that contributes to Inhibikase Therapeutics' financial success or failures. It also enables traders to predict the movement of Inhibikase Stock. The fundamental analysis module provides a way to measure Inhibikase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibikase Therapeutics stock.
Inhibikase | Cash And Equivalents |
Inhibikase Therapeutics Company Cash And Equivalents Analysis
Inhibikase Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Inhibikase Therapeutics Cash And Equivalents | 32.21 M |
Most of Inhibikase Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibikase Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inhibikase Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase Therapeutics is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Inhibikase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Inhibikase Therapeutics has 32.21 M in Cash And Equivalents. This is 96.08% lower than that of the Biotechnology sector and 92.8% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 98.81% higher than that of the company.
Inhibikase Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibikase Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inhibikase Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibikase Therapeutics by comparing valuation metrics of similar companies.Inhibikase Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Inhibikase Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 131.96 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 187.95 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 1,697 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 135.06 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.